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The influence of carbogen breathing on tumour tissue oxygenation in man
evaluated by computerised pO2 histography
S.J. Falk, R. Ward & N.M. Bleehen
MRC Unit and University Department ofClinical Oncology and Radiotherapeutics, Hills Road, Cambridge CB2 2QH, UK.
Summary Tumour tissue oxygenation has been measured in man during carbogen breathing (95% 02, 5%
C02) using a commercially available polarographic electrode system (Eppendorf P02 histograph). At least 200
tumour measurements in each of 17 patients with accessible tumours were taken before, and subsequently
continuously after the commencement of carbogen breathing for periods of 10 to 30min. In 12 out of 17
patients studied there was a significant increase in median tumour P02 during the first 10 min of carbogen
breathing (range 9 to 1800%). There was an initial rapid increase in tumour P02 which was maintained until 8
to 12 min, but then decreased throughout the subsequent treatment period. Although there was a reduction in
the proportion of point measurements < IOmmHg in 11 out of 13 patients, during carbogen breathing,
measured points of < 2.5 mmHg were only eliminated in three out of 11 tumours. The time course has
implications for the planning of clinical trials utilising radiotherapy with carbogen breathing.
The presence of hypoxic cells within tumours is widely
regarded as one major determinant of treatment failure in
patients following radical radiotherapy (Thomlinson & Gray,
1955). One approach to overcome tumour hypoxia, which
has been explored in the past is the use of carbogen
breathing (95%, 02, 5% C02), prior to and during radiation
treatment (Bush et al., 1977; Keresteci & Rider, 1973; Rubin
et al., 1979). Interest in this technique has been revived, in
association with modifiers of blood flow such as nicotina-
mide, following encouraging experimental results in mice
(Rojas, 1991).
There is substantial indirect evidence for hypoxia in human
tumours, including by histopathological observations (Thom-
linson & Gray, 1955), positron emission tomography (Beaney
et al., 1984), radiolabelled radiosensitising adducts (Urtasun
et al., 1986), and flow cytometric evaluation using fluor-
escence immunodetection (Hodgkiss et al., 1991). However,
because of a lack of suitable equipment, few direct measure-
ments of tumour tissue oxygenation have been performed in
patients until recently. We have used the polarographic elec-
trode system (Eppendorf P02 histograph) to measure directly
both normal and tumour tissue P02. This system uses reliable,
mechanically and electrically stable 350 ltm electrodes, that
move in programmable steps. A series of 200 measurements
can usually be completed in 10min, and this method has
provided further information on patterns of normal and
tumour tissue oxygenation (Kallinowski et al., 1990; Vaupel
et al., 1991; Hockel et al., 1991).
Clinical experience with carbogen breathing has been dis-
appointing to date. Studies in patients treated with radical
radiotherapy for bladder cancer (Keresteci & Rider, 1973),
and postoperative pelvic radiotherapy for stage 1-3 ovarian
cancer (Bush et al., 1977) in Toronto in the 1970's failed to
demonstrate a therapeutic benefit for carbogen breathing or
normobaric oxygen. Similarly, a large trial in advanced head
and neck cancer performed by the Radiation Therapy On-
cology Group (Rubin et al., 1979), showed no significant
improvement in loco-regional control or overall survival by
breathing carbogen. In each case patients breathed carbogen
for up to 2 h prior to treatment. However, in isotransplanted
syngenic mammary tumours in C3H mice, carbogen inhala-
tion for 0.5 min immediately before radiotherapy increased
the rate of cure (Inch et al., 1970), but this effect was reduced
in mice breathing carbogen for 12 min before and during
irradiation. Significantly, no advantage was demonstrated
over air breathing alone when the gas was breathed for I h.
The optimum duration of carbogen breathing, and its
timing with respect to X-irradiation, has therefore not been
established in human tumours. These factors may signifi-
cantly alter any therapeutic benefit gained from carbogen
breathing. As a preliminary investigation, before proceeding
to a combination with an agent that improves tumour per-
fusion and oxygenation such as nicotinamide (Horsman et
al., 1989), we have examined the response of tumour P02 to
carbogen breathing in unanaesthatised patients using the
Eppendorf PO2 histograph. In particular, we have addressed
the issue of the time course of events during carbogen
breathing, and its influence on tumour hypoxia.
Materials and methods
Patient characteristics
Seventeen patients with readily accessible superficial tumours
have entered the study following full informed consent.
Patients had a performance status WHO < 2, and had
received no specific anti-cancer therapy to the site examined
for at least 3 months. There was no history of respiratory or
cardiovascular disorders. Arterial blood gas estimations were
not performed. Measurements were performed in 15 epi-
thelial tumours, and two sarcomas. Details of individual
patients are shown in Table I. Tumours suitable for P02
measurements had a volume of at least 20 cm3, were not
cystic, highly vascular, or too firm for the needle probe to
traverse, and could be examined whilst the patient was
breathing carbogen. An initial series of at least 200 measure-
ments was obtained in tumour tissue with the patient supine
in a warm examination room. Patients then breathed car-
bogen through a closed system at a flow rate of 4-8 litres/
minute for periods up to 30min. This system comprised a
spacer as used for bronchodilator therapy (Allen & Hanbury,
UK), attached to a three way valve, such that all inhaled gas
by the patients was carbogen, and exhaled air was released to
the surrounding room. The mouth piece was a mouth gag,
similar to that employed by scuba divers, and a nose clip was
applied to prevent patients inhaling air during carbogen
administration. A further 200-300 measurements were then
obtained commencing shortly after the start of carbogen
breathing.
EppendorfP02 histography
Tissue oxygenation was assessed using the polarographic
electrode system (Eppendorf P02 histograph), after Flecken-
stein and Weiss (1984), construction of which has been des-
cribed elsewhere (Vaupel et al., 1991). Before and after each
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series of measurements the system was calibrated using sterile
buffered 0.9% sodium chloride pH 7.8 equilibrated alter-
nately with air and 100% nitrogen at room temperature for
at least 30 min. To eliminate inter-observer variation all
measurements were performed by one individual. Following
injection of local anaesthetic (without vasoconstrictor), the
350Am electrode was inserted through a 22G intravenous
cannula (Venflon, Viggo UK) to protect the probe from
unnecessary trauma in puncturing the skin. The electrode
was allowed to stabilise in normal subcutaneous tissue and
then advanced into tumour. The probe advanced stepwise in
programmable steps usually of 0.7 mm forwards, followed
immediately by a 0.3 mm backward motion in order to
minimise tissue compression artefacts. The probe was posi-
tioned initially under direct visual control and then at least
200 different measurements were taken in 7-10 paths, over
approximately Omin. The probe entered the tumour at an
angle whereby the maximum number of readings could be
taken reliably without patient discomfort through each study.
To ensure that the same region of the tumour was sampled
prior to and during carbogen therapy, whilst avoiding arte-
factual results due to prior tissue trauma from the electrode,
the tumour tissue sampled was changed after completion
each preset electrode path by rotating the probe 90 degrees
within its holder, and/or changing the angle of the electrode
path by 5-10 degrees. The maximum depth of tumour sam-
pled was 4 cm. Each individual measurement was displayed
as it was collected, and subsequently presented as frequency
histograms of tissue P02. Measurements obtained in
preliminary studies in untreated patients were considered
reproducable and reliable enough for us to examine the time
course of events during carbogen breathing. In addition
Hockel et al. (1991) found that there was no significant
difference in the number of values obtained in the lowest P02
class (0-2.5 mmHg) when a few electrode paths were com-
pared with multiple paths. All comparisons between different
series of measurements were performed by non-parametric
analysis of the central tendencies of change using the Mann-
Whitney 'U-test'.
The observed values represent point measurements within
tumour which may be viable or necrotic, and close to or far
from any blood vessel. We therefore present the data as
median values and as percentage change from pre-carbogen
breathing. Interpretation in terms of radiobiological hypoxia
is also difficult and we have defined readings < 10 mmHg as
being indicative of the likelihood of zones of radiobiological
hypoxia (Hall, 1987), with readings < 2.5 mmHg being
defined as less than half maximum radiosensitivity (Vaupel et
al., 1991).
tological type. These findings confirm previously reported
data using this measuring system (Kallinowski et al., 1990).
TumourP02 measurements during carbogen breathing
Table I details the changes in median P02 recorded in each
tumour during the first 10 min of carbogen breathing. In 12
out of 17 patients there was a significant increase (Mann-
Whitney U test; P < 0.0483) in median tumour tissue P02
whilst breathing carbogen (range 9 to 1800%). This wide
range of variation was not altered by the total duration of
carbogen breathing (data not shown), tumour type, or vol-
ume. In four of the remaining five patients there was no
significant change in tumour P02 during carbogen breathing
when the data was evaluated by the Mann-Whitney U-test
(P > 0.0612). In the remaining patient the biological
significance of an apparent decrease in median P02 could not
be assessed because the full data set was not available.
Carbogen breathing alters the pattern of oxygen distribu-
tion within human tumours. Figure lb (from a representative
patient) shows that there was a much greater variation in
individual values, and an increase in high values up to
300 mmHg, however, low values of P02 were not eradicated
(Table I). Radiobiologically hypoxic values (< 10 mmHg)
were recorded in 13 out of the 17 tumours studied. In 11 out
of these 13 patients there was a decrease in the percentage of
values < 10 mmHg during carbogen breathing, however the
magnitude of that reduction was not consistent. Table I
further shows that values < 2.5 mmHg (representing less
than half maximum radiosensitivity) were eradicated by car-
bogen breathing in only three out of 11 patients in whom
such values were recorded in initial measurements.
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Results
Tumour P02 (mmHg)
TumourP02 measurements prior to breathing carbogen
Measurements in normal subcutaneous tissue and muscle
have been performed in 20 patients and reported elsewhere
(Bleehen et al., 1991). Median P02 in these tissues was
31 mmHg. Values obtained ranged from 0 to 80 mmHg, and
tended towards a pattern of a normal distribution.
A series of 200 measurements in each tumour was per-
formed prior to carbogen breathing. Compared with normal
tissue, tumour P02 histograms in general demonstrate a shift
of the distribution to the left. This relative lack of high
values and a preponderance of lower P02 values suggests the
presence of tissue hypoxia, rather than high oxygen respira-
tion rates (Figure la). Table I shows the histological type,
site, size, and median P02 of the tumours examined. There
was marked intertumour variability with well oxygenated and
poorly oxygenated tumours observed, e.g. median P02 in the
five breast tumours studied ranged from 5 to 50 mmHg. No
association was observed between median tissue oxygenation
and tumour volume, haemoglobin concentration, or his-
tological grade of tumour (data not shown) in any his-
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Figure 1 Frequency histogram of tumour P02 in a patient with
locally recurrent anaplastic carcinoma of thyroid, 6 years follow-
ing radical radiotherapy. a, prior to carbogen breathing. b, during
carbogen breathing.
-
11922 S.J. FALK et al.
Time course ofchanges in tumourP02 during carbogen
breathing
The time course of changes in tumour P02 was investigated
by pooling between 35 and 60 individual readings obtained
over 2-4 min periods during carbogen breathing in 11
patients. Patients were asked to breathe carbogen for as long
as they could comfortably manage, and the total duration of
carbogen breathing ranged from 10 to 30 min. Figure 2
illustrates the response in three patients in whom there were
significant increases in median P02 during the first 10 min of
carbogen breathing. Maximum median tumour P02 was ob-
served at between 8 and 12 min. In each patient demon-
strated there was a subsequent decline in median P02 between
12 and 18 min. In two out of the three patients shown this
decline in tumour P02 was statistically significant (Mann-
Whitney U-test, P < 0.0271).
Figure 3 shows a plot of individual point measurements in
a patient with multiple untreated subcutaneous nodules due
to metastatic melanoma with apparent sensitisation by car-
bogen breathing. In this patient hypoxic values < 2.5 mmHg
were abolished, and values < 10 mmHg were reduced from
23 to 9%. Median P02 rose rapidly initially, but declined to a
small increase above air breathing levels at 18 min which
remained a significant increase when values obtained prior to
breathing carbogen were compared to those obtained be-
tween 18 and 20 min (P = 0.0439). Between 11 and 13 min
median P02 was 67 mmHg and this declined significantly to
12 mmHg between 16 and 19 min (P = 0.0325). In contrast
Figure 4 shows the individual point measurements obtained
prior to and during carbogen breathing in a patient with
extensive small cell lung cancer with multiple subcutaneous
nodules, who had received no prior anti-cancer therapy. In
this patient carbogen breathing had no apparent effect on
either median P02, and neither was there sensitisation of
hypoxic values.
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Figure 3 The effects of carbogen breathing on a subcutaneous
deposit of untreated metastatic melanoma, showing apparent sen-
sitisation of hypoxic values. 0, individual measurement.
median tumour P02 pooled from 30 to 50 individual measure-
ments.
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Figure 2 Time course of change in median tumour P02 during
carbogen breathing. Each point represents the median value of 30
to 50 individual measurements. 0, lymph node, small cell lung
cancer. 0, lymph node, large cell carcinoma bronchus. A, sub-
cutaneous deposit, small cell lung cancer.
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Figure 4 The effects of carbogen breathing on a subcutaneous
deposit of untreated extensive small cell lung cancer showing no
effect on tumour P02 or hypoxic values. 0, individual measure-
ment. , median tumour PO2 pooled from 30 to 50 individ-
ual measurements.
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Discussion
We have demonstrated that the Eppendorf P02 histograph
electrode system is well tolerated by patients, reliable, and
has shown consistent changes in tumour P02 during carbogen
breathing. Carbogen breathing significantly increased median
tumour P02 in 12 out of the 17 patients studied. The increase
in tumour P02 however was extremely variable. This confirms
previous observations by Evans and Naylor (1963), who
showed that breathing 100% oxygen at one atmosphere pro-
duced an increase in tumour oxygen tension in 20 out of 22
single microelectrode measurements in five patients.
Kolstad (1968) used single microelectrode measurements in
cervical cancer and showed that there was a rapid increase in
tumour P02 after a latency period of 20-30 s following the
commencement of patients breathing atmospheric oxygen. In
some tumours studied, particularly with more advanced
disease, there was no apparent increase in tumour oxygena-
tion during oxygen breathing, and the rise in tumour P02 was
slower than that of normal tissue. We have demonstrated
that tumour P02 does rise rapidly initially, and continues to
increase up to 8- 12 min after the commencement of car-
bogen breathing. This has been attributed to the 5% CO2 in
carbogen causing vasodilatation, tachycardia, increased res-
piratory drive, and thus improved tissue oxygen delivery
(DuSault, 1963). Consistent with this hypothesis we have
observed a 55% increase in red blood cell flux measured by
an implantable probe, using laser doppler flowmetry, in a
patient with locally advanced carcinoma of breast in the first
5 min of carbogen breathing (unpublished data). However
when carbogen breathing was continued up to 18 min there
was a reduction in median tumour P02.
Normobaric oxygen was breathed for periods up to 2 h in
patients with transitional cell carcinoma of the bladder prior
to radical radiotherapy, with no improvement in survival
(Keresteci & Rider, 1973). Similarly, there was no difference
in the relapse free survival in patients with post-operative
stage 1-3 ovarian cancer treated with pelvic irradiation, who
breathed carbogen immediately before and during treatment
(Bush et al., 1977). A large trial of carbogen breathing was
undertaken by the RTOG in 254 patients treated with radical
radiotherapy for advanced carcinomas of the head and neck
(Rubin et al., 1979). Patients breathed 100% 02 for 10 to
20 min, and then carbogen for periods of 15-30 min prior to,
and during treatrnent. This failed to show any improvement
in either overall survival, or loco-regional control, however,
there was no increase in toxicity.
One clinical trial has shown a small therapeutic advantage
to breathing atmospheric oxygen 5-10 min prior to and
during radical external beam radiotherapy for stage II car-
cinoma of cervix (Bergsjo & Kolstad, 1968; 33.1% local
failure in controls compared to 30.1% in oxygen breathing).
Interestingly, there were only 22.4% local failures in that
group of patients that breathed atmospheric oxygen for
15 min in each hour during a 120 h radium insertion as well
as during external beam therapy, although the difference was
not statistically significant.
The pre-irradiation breathing time has been shown to be of
considerable importance in the radiosensitisation by carbogen
breathing of tumours in mice (Inch et al., 1970). Further
studies in mice have confirmed a time dependence of thera-
peutic gain with carbogen breathing, and it has been pos-
tulated that this may be due to variations in tumour blood
flow, rather than changes in oxygen dissociation (Siemann et
al., 1977). Previous clinical trials may therefore have failed to
show an improvement in tumour control with carbogen
breathing on account of suboptimal timing. Our data suggest
that the optimal increase in tumour P02 by carbogen occurs
in the first 12 min, and therefore carbogen breathing in any
future clinical trials should commence immediately before the
first radiation field is treated, without any preliminary 'soak-
ing' period.
Many patients found breathing carbogen through our
closed system difficult and claustrophobic. The maximum
tolerated time of carbogen breathing was 30min, although
ten of our patients, usually with advanced and metastatic
disease could only manage the mask inside their mouths for
periods of 10-20 min. This system is therefore unlikely to be
suitable for the use of carbogen breathing in routine clinical
practice, and a more acceptable system needs to be devel-
oped.
Pooled data from experiments performed in yeast, bacteria
and mammalian cells suggest that oxygen concentrations of
0.5% or approximately 3 mmHg corresponds to less than
half maximum radiosensitivity (Hall, 1987), and values < 10
mmHg correspond to reduced radiosensitivity. Whilst the
proportion of hypoxic values < 10mmHg (identified in 13
out of 17 tumours studied) fell in 11 of these tumours studied
during the first 10 min of carbogen breathing, values < 2.5
mmHg (where present in initial measurements) were only
abolished in three out of 11 tumours. These findings are
consistent with experimental findings and mathematical mod-
elling of carbogen breathing in DS-carcinosarcoma (Vaupel,
1977), which predicted that owing to the limited diffusion of
oxygen eradication of hypoxic areas could only occur at the
arterial end of a capillary supply system.
This electrode technique however cannot differentiate be-
tween low P02 values in necrotic non-viable tissue, and more
importantly low P02 values due to hypoxic, yet clonogenically
viable malignant cells. Neither can it differentiate between
values obtained from viable tumour cells, and supporting
non-malignant stroma, or distinguish between oxygen-defi-
cient areas and areas with high consumption rates creating
steep P02 gradients, such that low P02 values are apparently
measured in the absence of metabolic hypoxia. This issue is
in part addressed by the large number of individual readings
(200-430) taken during carbogen breathing in this study.
However, our results show an incomplete reduction of mea-
sured points < 10 mmHg in tumour at presumed radiobio-
logically hypoxic P02 levels during carbogen breathing. This
suggests that carbogen breathing alone, even when given with
optimal timing relative to X-radiation is unlikely to produce
a marked therapeutic gain. Further studies with additional
agents to modify tumour perfusion are needed and are in
progress.
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